Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation
| Autor: | Steen Walter, J.K. Kristensen, T.L. Dahm, R.B. Rasmussen, P. Ostri, M. Nøhr, C. Frimodt-Møller, N. Alexander |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
medicine.medical_specialty Adenoma Urology medicine.medical_treatment media_common.quotation_subject Prostatic Hyperplasia Placebo Urination Muscle hypertrophy Double blind Double-Blind Method Prostate medicine Humans media_common Aged Aged 80 and over Chemotherapy business.industry Parasympatholytics Middle Aged medicine.disease Urination Disorders Surgery Flavoxate medicine.anatomical_structure business medicine.drug |
| Zdroj: | Urologia internationalis. 55(4) |
| ISSN: | 0042-1138 |
| Popis: | To investigate the effect of flavoxate (Urispadol®) treatment on patients with symptomatic benign prostatic hypertrophy (BPH), with the main weight on the irritative symptoms, a randomized, double-blind, parallel-group, placebo-controlled and multicenter investigation was carried out. Seventy patients entered the study, 37 were allocated to flavoxate treatment on a daily dose of 1,200 mg (400 mg t.i.d.) for 12 weeks, and 33 patients were allocated to placebo treatment. In spite of a sufficient power, the study did not discriminate the two treatment groups in a statistically significant way (p > 0.05), when considering the main endpoints: the irritative symptom score and the global patient evaluation. Conservative treatment of micturition disorders accompanying BPH with flavoxate in doses of 1,200 mg/day cannot be recommended for clinical use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|